Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Tijssen

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 6, 2016
Does acute coronary syndrome impact on the incidence of thrombosis after the implantation of an Absorb bioresorbable vascular scaffold?Yohei Sotomi, Yosuke Miyazaki, Carlos Collet, et al.
European Heart Journal|August 30, 2020
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trialPascal Vranckx, Marco Valgimigli, Lars Eckardt, et al.
JACC. Cardiovascular Interventions|March 24, 2012
Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion studyInge Wijnbergen, Harold Helmes, Jan Tijssen, et al.
Minerva Cardioangiologica|September 15, 2016
Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studiesCarlos Collet, Taku Asano, Yohei Sotomi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 21, 2022
A randomized trial of non-fasting vs. fasting for cardiac implantable electronic device procedures (Fast-CIED Study)Kerstin Bode, Matthias Gerhards, Michael Doering, et al.
European Heart Journal|January 13, 2006
Adherence to guidelines in the clinical care for adults with congenital heart disease: the Euro Heart Survey on adult congenital heart diseasePeter Engelfriet, Jan Tijssen, Harald Kaemmerer, et al.
European Heart Journal|July 6, 2005
The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart diseasePeter Engelfriet, Eric Boersma, Erwin Oechslin, et al.
Lancet (London, England)|September 8, 2019
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trialPascal Vranckx, Marco Valgimigli, Lars Eckardt, et al.
European Heart Journal|May 10, 2026
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trialPeter van der Meer, Dirk J van Veldhuisen, Geert H D Voordes, et al.
American Heart Journal|November 29, 2016
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO studyStephan Windecker, Jan Tijssen, Gennaro Giustino, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 6, 2016
Does acute coronary syndrome impact on the incidence of thrombosis after the implantation of an Absorb bioresorbable vascular scaffold?Yohei Sotomi, Yosuke Miyazaki, Carlos Collet, et al.
European Heart Journal|August 30, 2020
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trialPascal Vranckx, Marco Valgimigli, Lars Eckardt, et al.
JACC. Cardiovascular Interventions|March 24, 2012
Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion studyInge Wijnbergen, Harold Helmes, Jan Tijssen, et al.
Minerva Cardioangiologica|September 15, 2016
Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studiesCarlos Collet, Taku Asano, Yohei Sotomi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 21, 2022
A randomized trial of non-fasting vs. fasting for cardiac implantable electronic device procedures (Fast-CIED Study)Kerstin Bode, Matthias Gerhards, Michael Doering, et al.
European Heart Journal|January 13, 2006
Adherence to guidelines in the clinical care for adults with congenital heart disease: the Euro Heart Survey on adult congenital heart diseasePeter Engelfriet, Jan Tijssen, Harald Kaemmerer, et al.
European Heart Journal|July 6, 2005
The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart diseasePeter Engelfriet, Eric Boersma, Erwin Oechslin, et al.
Lancet (London, England)|September 8, 2019
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trialPascal Vranckx, Marco Valgimigli, Lars Eckardt, et al.
European Heart Journal|May 10, 2026
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trialPeter van der Meer, Dirk J van Veldhuisen, Geert H D Voordes, et al.
American Heart Journal|November 29, 2016
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO studyStephan Windecker, Jan Tijssen, Gennaro Giustino, et al.
Pageof 5